Publication at Faculty of Medicine in Hradec Králové |
2023
Abstract
Up to 10% of adults and 2.5% of children with asthma have severe asthma with reduced quality of life and increased risk of exacerbations. In asthmatic patients with eosinophilic airway inflammation add-on treatment with biologic therapies may be needed.
From 2015 anti-interleukin-5 therapy with mepolizumab has been registered in the EU. In this case we present a patient with severe type-2 high asthma who has been treated with mepolizumab.
This therapy has led to increased quality of life, reduced rate of asthma exacerbations and reduced dose of rescue inhaler therapy and chronic oral glucocorticoid therapy.